Physician profile
Christopher G Wang
NPI 1083856157
$22,014.53
in general payments reported to CMS, 2019-2025
78 companies · $3,313 in 2025
The $3,313 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,994 · 2020: $1,907 · 2021: $4,641 · 2022: $2,892 · 2023: $2,694 · 2024: $3,573 · 2025: $3,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,554 · Education: $26.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,553.69 |
| Education | $26.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,631.34 | 2019-2025 | Enhertu, Imfinzi, Calquence |
| Novartis Pharmaceuticals Corporation | $1,626.01 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,311.68 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $942.25 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $905.59 | 2019-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Amgen INC. | $877.47 | 2019-2023 | Kyprolis |
| E.R. Squibb & Sons, L.L.C. | $846.69 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Abbvie INC. | $842.63 | 2019-2025 | Venclexta |
| Seagen INC. | $729.50 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Pfizer INC. | $692.46 | 2019-2025 | |
| Celgene Corporation | $637.69 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Genentech USA, INC. | $578.41 | 2019-2025 | Polivy, Lunsumio, Tecentriq |
| Eisai INC. | $560.47 | 2019-2025 | |
| Exelixis INC. | $498.58 | 2019-2025 | Cabometyx |
| Daiichi Sankyo INC. | $476.64 | 2019-2025 | Enhertu, Datroway |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $457.47 | 2019-2025 | Jemperli, Ojjaara, Zejula |
| Incyte Corporation | $456.01 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Octapharma USA, INC. | $429.28 | 2021-2025 | Octagam Immune Globulin (Human) |
| Bayer Healthcare Pharmaceuticals INC. | $423.44 | 2019-2025 | |
| Lilly USA, LLC | $343.04 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $334.85 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $310.05 | 2019-2025 | Ultomiris, Soliris |
| Gilead Sciences, INC. | $301.57 | 2019-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $286.65 | 2019-2023 | Imbruvica, Epkinly |
| Astellas Pharma US INC | $257.50 | 2019-2025 | Xtandi, Xospata, Padcev |
| Aveo Pharmaceuticals, INC. | $207.41 | 2021-2025 | Fotivda |
| Kite Pharma, INC. | $204.32 | 2020-2025 | Yescarta |
| Deciphera Pharmaceuticals INC. | $202.76 | 2020-2025 | Qinlock, Romvimza, Tgct |
| Array Biopharma INC | $200.25 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Regeneron Healthcare Solutions, INC. | $193.76 | 2019-2025 | Libtayo, Lynozyfic |
| Ipsen Biopharmaceuticals, INC | $191.67 | 2019-2024 | Onivyde, Somatuline Depot |
| Beigene USA, INC. | $155.39 | 2020-2025 | Brukinsa, Tevimbra |
| Myriad Genetic Laboratories, INC. | $142.63 | 2021-2024 | Myrisk, Precisetumor |
| Csl Behring | $128.56 | 2020-2025 | Hizentra |
| Sobi, INC | $126.14 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $126.03 | 2021-2025 | Monoferric |
| Ethicon INC. | $125.00 | 2019 | |
| Advanced Accelerator Applications | $124.24 | 2019 | |
| Beone Medicines USA, INC. | $122.56 | 2025 | Brukinsa, Tevimbra |
| Blueprint Medicines Corporation | $121.18 | 2021-2024 | Ayvakit |
| Taiho Oncology, INC. | $101.60 | 2020-2024 | |
| Tempus Ai, INC | $99.93 | 2024 | |
| Emd Serono, INC. | $98.07 | 2019-2025 | |
| Boston Scientific Corporation | $97.46 | 2024 | |
| Kyowa Kirin, INC. | $95.67 | 2019-2025 | Poteligeo |
| Karyopharm Therapeutics INC. | $80.43 | 2020-2022 | |
| Epizyme, INC. | $77.33 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.20 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $74.67 | 2020-2024 | |
| Mirati Therapeutics, INC. | $72.47 | 2023-2024 | Krazati |
| Tersera Therapeutics LLC | $68.28 | 2022-2023 | Xermelo |
| Morphosys, US INC. | $64.48 | 2022-2023 | Monjuvi |
| Dova Pharmaceuticals | $60.79 | 2020-2021 | |
| Novocure INC. | $57.86 | 2021-2025 | Optune Lua (Novottf-200t) |
| Apellis Pharmaceuticals, INC. | $57.73 | 2023-2025 | Empaveli |
| Janssen Pharmaceuticals, INC | $57.41 | 2019-2022 | |
| Springworks Therapeutics, INC. | $55.88 | 2024-2025 | Ogsiveo |
| Tesaro, INC. | $54.70 | 2019 | |
| Sumitomo Pharma America, INC. | $54.21 | 2023-2025 | Orgovyx |
| Genmab U.S., INC. | $51.57 | 2023-2025 | Epkinly |
| Caris Mpi, INC. | $42.65 | 2025 | Mi Cancer Seek |
| Rigel Pharmaceuticals, INC. | $38.40 | 2019-2024 | Rezlidhia, Tavalisse |
| Immunogen, INC. | $36.60 | 2023-2024 | Elahere, Elahere |
| Adaptive Biotechnologies Corporation | $34.19 | 2023-2025 | Clonoseq |
| Servier Pharmaceuticals LLC | $32.88 | 2024 | |
| Pharmaessentia USA Corporation | $31.59 | 2023 | Besremi |
| Helsinn Therapeutics (U.S.), INC. | $29.60 | 2019 | |
| Myovant Sciences INC. | $28.04 | 2021 | |
| Acrotech Biopharma INC. | $23.81 | 2022 | |
| Adc Therapeutics America, INC. | $22.13 | 2023 | |
| Sirtex Medical INC | $21.97 | 2019 | |
| Stemline Therapeutics INC. | $19.89 | 2024 | Orserdu |
| Puma Biotechnology, INC. | $18.23 | 2021 | |
| Accord Healthcare, INC. | $15.50 | 2023 | |
| Foundation Medicine, INC. | $15.46 | 2020 | |
| Fennec Pharmaceuticals, INC. | $14.08 | 2025 | Fyarro |
| Clovis Oncology, INC. | $3.60 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Keytruda $588Kisqali $411Enhertu $409Venclexta $328Ninlaro $282Imbruvica $251Epkinly $227Reblozyl $222Xtandi $216Scemblix $207Darzalex $200Lynparza $197Octagam Immune Globulin (Human) $190Tecvayli $184Opdivo $175Fotivda $173Brukinsa $166Cabometyx $160Lenvima $157Polivy $154Verzenio $149Jaypirca $149Tukysa $146Imfinzi $140Calquence $137Monjuvi $126Opdualag $124Rybrevant $118Pluvicto $115Orgovyx $114Adcetris $114Onivyde $114Jakafi $109Talzenna $108Hizentra $105Fruzaqla $102Braftovi $102Mektovi $102Elahere $99.10Ibrance $99.08Nubeqa $98.66Xofigo $98.66Qinlock $97.50Krazati $97.02Somatuline Depot $96.20Jemperli $95.11Lunsumio $94.78Yescarta $93.83Monoferric $92.90Sarclisa $91.56Ojjaara $90.35Libtayo $87.74Ayvakit $87.60Elrexfio $85.52Tecentriq $83.17Pemazyre $82.42Doptelet $80.47Padcev $78.28Tasigna $77.36Fabhalta $75.19Columvi $74.94Carvykti $72.35Talvey $70.75Trodelvy $69.53Vitrakvi $65.96Stivarga $65.96Bosulif $63.88Tevimbra $62.44Welireg $60.47Tivdak $57.89Ultomiris $57.74Empaveli $57.73Retevmo $57.43Erleada $56.26Ogsiveo $55.88Lorbrena $53.76Alunbrig $50.24Mekinist $48.62Pomalyst $48.60Comirnaty $47.48Inlyta $47.34Vonjo $45.67Myrisk $45.60Precisetumor $45.01Xospata $43.64Lonsurf $43.35Inqovi $43.35Mi Cancer Seek $42.65Piqray $40.33Creon $40.18Iclusig $40.17Poteligeo $38.46Clonoseq $34.19Xermelo $32.98Xalkori $32.92Phesgo $31.87Besremi $31.59Promacta $30.81Datroway $28.54Zepzelca $28.20
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.